Abstract
Computer simulations of the human alpha(1d)-adrenergic receptor (alpha(1d)-AR) based on the crystal structure of rhodopsin have been combined with experimental site-directed mutagenesis to investigate the role of residues in the transmembrane domains in antagonist binding. Our results indicate that the amino acids Asp176 in the third transmembrane domain (TMD), Glu237 in TMD IV, and Ser258 in TMD V of alpha(1d)-AR were directly involved in prazosin and tamsulosin binding. The Asp176Ala mutant did not exhibit any affinity for [(3)H]prazosin and neither did it show agonist-stimulated inositol phosphates (IP) formation. On the other hand, the Glu237Ala and Ser258Ala mutant alpha(1d)-AR showed increased binding affinity for [(3)H]prazosin. Competition binding experiments showed that prazosin affinity had increased to 5-fold and 3-fold in the Glu237Ala and Ser258Ala mutants, respectively, versus wild-type; and tamsulosin affinity only increased in the Ser258Ala mutant (2-fold vs wild-type). It seems that these two residues constrain the receptor by interaction with other residues and this disruption of the interaction increased the receptor's binding affinity towards antagonists. However, the Glu237Ala and Ser258Ala mutant receptors...Continue Reading
References
May 7, 1976·Analytical Biochemistry·M M Bradford
May 1, 1989·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·C D StraderR A Dixon
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S CotecchiaB K Kobilka
Jul 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·C D StraderR A Dixon
Sep 29, 1995·The Journal of Biological Chemistry·J HwaD M Perez
Mar 8, 1996·The Journal of Biological Chemistry·D G RokoshP C Simpson
Mar 15, 1996·The Journal of Biological Chemistry·J Hwa, D M Perez
Aug 1, 1996·Cellular Signalling·R D GuarinoM T Piascik
Nov 12, 1996·Biochemistry·N HamaguchiP W Jeffs
Dec 9, 1996·FEBS Letters·A CavalliS Cotecchia
Apr 1, 1997·Naunyn-Schmiedeberg's Archives of Pharmacology·M YangM C Michel
Dec 18, 1998·Molecular Pharmacology·T WurchP J Pauwels
May 29, 1999·The Journal of Biological Chemistry·S ChenR M Graham
Feb 25, 2000·European Journal of Pharmacology·J A García-SáinzL del Carmen Medina
Apr 15, 2000·The Journal of Biological Chemistry·D J WaughD M Perez
May 2, 2001·The Journal of Biological Chemistry·D J WaughD M Perez
Apr 9, 2002·Pharmacology·Malika IsrailovaIkunobu Muramatsu
Sep 25, 2002·Life Sciences·Masaji IshiguroTakafumi Nagatomo
Feb 20, 2003·European Journal of Pharmacology·Andre S PupoKenneth P Minneman
Aug 2, 2006·Biological & Pharmaceutical Bulletin·Habib Abul MuntasirTakafumi Nagatomo
Oct 21, 2006·Biochemical Pharmacology·Dianne M Perez
Jul 5, 2007·Journal of Pharmacological Sciences·Habib Abul MuntasirTakafumi Nagatomo
Oct 6, 2007·Biological & Pharmaceutical Bulletin·Kazuya TakahashiTakafumi Nagatomo
Citations
Jul 6, 2014·European Journal of Medicinal Chemistry·Giuseppe RomeoKenneth P Minneman
May 10, 2011·European Journal of Medicinal Chemistry·Luiz A S RomeiroCarlos A M Fraga
Apr 3, 2014·European Journal of Pharmacology·Adrian P CampbellAngela M Finch
Dec 3, 2014·FEBS Letters·Arhamatoulaye MaïgaNicolas Gilles
Mar 29, 2011·Pharmacological Reports : PR·Ivan KocićPiotr Rekowski
Jan 9, 2020·The American Journal of Drug and Alcohol Abuse·Daryl I ShorterDavid A Nielsen